Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy

Lupus

Volumn 22, Issue 5, 2013, Pages 527-537

  Moon, S J ^a   Park, H S ^a   Kwok, S K ^a   Ju, J H ^a   Choi, B S ^a   Park, K S ^a   Min, J K ^a   Kim, H Y ^a   Park, S H ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Anti DNA antibodies; Nephritis; Systemic Lupus Erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LUPUS ANTICOAGULANT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENERAL PATHOLOGICAL PARAMETERS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KOREA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONSET AGE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; BIOPSY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84875959837     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313476357     Document Type: Article

References (39)

1. Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci. 2009 ; 24: S7-10 - S7-10
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 ; 78: 167-175
3. Bruce IN. 'Not only.... but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005 ; 44: 1492-1502
4. Manger K, Kusus M, Forster C, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis. 2003 ; 62: 846-850
5. Moon SJ, Kwok SK, Ju JH, et al. Predictors of chronic kidney disease in Korean patients with lupus nephritis. J Rheumatol. 2011 ; 38: 2588-2597
6. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford). 2011 ; 50: 1424-1430
7. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002 ; 46: 995-1002
8. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996 ; 50: 2047-2053
9. Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol. 1994 ; 23: 142-144
10. Ciruelo E, de la Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 1996 ; 39: 2028-2034
11. Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol. 2011 ; 75: 233-241
12. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology (Oxford). 2010 ; 49: 128-140
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
14. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
15. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432.
16. Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983 ; 75: 382-391
17. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005 ; 14: 265-272
18. So MW, Koo BS, Kim YG, Lee CK, Yoo B. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: A retrospective analysis. Clin Rheumatol. 2011 ; 30: 1399-1405
19. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000 ; 57: 258-264
20. Gibson KL, Gipson DS, Massengill SA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: Focus on children, adolescents, and young adults. Clin J Am Soc Nephrol. 2009 ; 4: 1962-1967
21. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004 ; 50: 2559-2568
22. Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002 ; 61: 1502-1509
23. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004 ; 50: 3934-3940
24. Moon SJ, Park HS, Kwok SK, Ju JH, Kim HY, Park SH. Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol 2012 [Epub ahead of print].
25. Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: A slowly changing landscape. Nat Rev Nephrol. 2011 ; 7: 96-109
26. Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010 ; 25: 3939-3948
27. Daleboudt GM, Broadbent E, McQueen F, Kaptein AA. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 ; 63: 342-350
28. Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sjogren's syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am. 1992 ; 18: 337-358
29. Mond CB, Peterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum. 1989 ; 32: 202-204
30. Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, Piette JC. Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus. 2005 ; 14: 660-664
31. Shahin AA, Shahin HA, Hamid MA, Amin MA. Cardiac involvement in patients with systemic lupus erythematosus and correlation of valvular lesions with anti-Ro/SS-A and anti-La/SS-B antibody levels. Mod Rheumatol. 2004 ; 14: 117-122
32. Chien JW, Lin CY, Yang LY. Correlation between anti-Ro/La titers and clinical findings of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi (Taipei). 2001 ; 64: 283-291
33. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000 ; 35: 904-914
34. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol. 2007 ; 18: 244-254
35. Cortes-Hernandez J, Ordi-Ros J, Labrador M, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus. 2003 ; 12: 287-296
36. Bolton WK, Schrock JH, Davis JS. Rheumatoid factor inhibition of in vitro binding of IgG complexes in the human glomerulus. Arthritis Rheum. 1982 ; 25: 297-303
37. Isenberg DA, Shoenfeld Y, Schwartz RS. Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum. 1984 ; 27: 132-138
38. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum. 1979 ; 22: 226-235
39. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986 ; 45: 359-366